Podcasts about america idsa

This StAR episode features the CID State-of-the-Art Review on Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects.Our guest stars this episode are:Minh-Vu Nguyen (UC Davis Health)Charles Daley (National Jewish Health, University of Colorado, Icahn School of Medicine at Mt Sinai)Reeti Khare (National Jewish Health)Journal article link: Nguyen MH, Haas MK, Kasperbauer SH, et al. Nontuberculous Mycobacterial Pulmonary Disease: Patients, Principles, and Prospects. Clin Infect Dis. 2024;79(4):e27-e47. doi:10.1093/cid/ciae421Journal companion article - Executive summary link: https://academic.oup.com/cid/article-abstract/79/4/805/7823163From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Till Koch and Annette Hennigs join to discuss their ID podcast Infektiopod and dive into varicella!Check out Infektiopod here!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Sumanth Cherukumilli, Milagritos Tapia, and Adama Mamby Keita join Febrile to describe an approach to a gray membranous pharyngitis!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Dr. Adam Ratner joins to discuss a case of facial swelling which leads to a conversation about vaccine hesitancy and current outbreaks.Check out Booster Shots: The Urgent Lessons of Measles and the Uncertain Future of Children's Health !Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Morgan Hui, Jonathan Darby, Max Olenski, and Catriona Halliday join Febrile from Australia to share a unique case of a transplant recipient with a painless lump.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Chelsea Gorsline, Courtney Harris, and Rebecca Kumar join to tell us more about the Transplant ID Early Career Network and how to approach donor call!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on Ocular Infections.Our guest stars this episode are:Miriam Barshak (Massachusetts General Hospital; Mass Eye and Ear)Akash Gupta (University of Pittsburgh Medical Center)Journal article link: Barshak MB, Durand ML, Gupta A, Mohareb AM, Dohlman TH, Papaliodis GN. State-of-the-Art Review: Ocular Infections. Clin Infect Dis. 2024;79(5):e48-e64. doi:10.1093/cid/ciae433Journal companion article - Executive summary link: https://academic.oup.com/cid/article-abstract/79/5/1125/7906419From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode of the Conscious Design Podcast, Ian Peterman interviews Ravi Sawhney, founder and CEO of RKS Design, a global human-centered design firm. Ravi shares his journey in industrial design, the development of his Psycho-Aesthetics® methodology, and how emotional durability and sustainable materials are shaping the future of innovation in product design.They discuss Ravi's groundbreaking work on electric guitars, including a collaboration with Dave Mason to create the world's first sustainable electric guitar. The conversation dives into circular economy principles and how businesses can successfully integrate aesthetics, function, and sustainability to make a lasting impact.

Drs. Tom Schmidt, George R Thompson, and Nate Bahr solve a pneumonia not responding to antimicrobials and discuss endemic fungal disease!To learn more about the Mycoses Study Group Research and Education Consortium, check out the MSGERC pageEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on delusional infestation.Our guest stars this episode are: Alexandra Mendelsohn (Dell Medical School, University of Texas Austin)Alysse Wurcel (Boston Medical Center)Journal article link: https://academic.oup.com/cid/article-abstract/79/2/e1/7718272Journal companion article - Executive summary link: https://academic.oup.com/cid/article-abstract/79/2/287/7718273From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In our Season 4 finale wrapping up 2024, Febrile is excited to host our biggest guest list yet to discuss the importance of International Medical Graduates (IMGs) in infectious diseases! Our guests:Ana Del Valle (Pediatric ID faculty at Arkansas Children's Hospital)Cristina Tomatis (Pediatric ID faculty at Nationwide Children's Hospital)Diego Cruz (Current pediatric resident and recent graduate of pediatric ID fellowship program at Nationwide Children's Hospital)Radhika Sheth (Adult ID faculty at Henry Ford Health System)Shweta Anjan (Adult ID faculty at University of Miami and Jackson Memorial Hospital)Zheyi Teoh (Pediatric ID faculty at Seattle Children's Hospital)Cesar Berto (Adult ID faculty at University of Alabama Birmingham)Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In the beauty industry, water conservation is everyone's business. And for even one brand to launch one product that moves things forward, it's a collective effort—involving ingredient tech, manufacturing processes, and packaging design along with feedback from consumers and salon professionals.  This week on the CosmoFactory podcast, we're learning about an eco-chic powder-to-lather shampoo. Our guest is Stephane Farsht, CEO and Co-Founder of a newly launched professional hair care brand called Small Wonder. This US-based brand is dedicated to advancing the performance of hair care and treatment products while simultaneously helping the cosmetics industry become more environmentally sustainable by reducing water waste, packaging waste, logistics waste, etc. Launched just this year (in 2024), Small Wonder has been honored with an award from Marie Claire, a Cosmoprof Award at this summer's North American edition of the show in Las Vegas, and an IDEA award from the Industrial Designers Society of America (IDSA) for the brand's custom packaging. If you appreciated this episode, SUBSCRIBE to the CosmoFactory podcast & please LEAVE US A REVIEW today. With your help, even more cosmetic industry professionals can discover the inspiring interviews we share on CosmoFactory! ABOUT CosmoFactoryBeauty industry stakeholders listen to the CosmoFactory podcast for inspiration and for up-to-date information on concepts, tactics, and solutions that move business forward. CosmoFactory – Ideas to Innovation is a weekly interview series for cosmetics and personal care suppliers, finished product brand leaders, retailers, buyers, importers, and distributors. Each Tuesday, CosmoFactory guests share experiences, insights, and exclusive behind-the-scenes details—which makes this not only a must-listen B2B podcast but an ongoing case study of our dynamic industry. Guests are actively working in hands-on innovation roles along the beauty industry supply chain; they specialize in raw materials, ingredients, manufacturing, packaging, and more. They are designers, R&D or R&I pros, technical experts, product developers, key decision makers, visionary executives. HOST Deanna UtroskeCosmetics and personal care industry observer Deanna Utroske hosts the CosmoFactory podcast. She brings an editorial perspective and a decade of industry expertise to every interview. Deanna is also Editor of the Beauty Insights newsletter and a supply-side positioning consultant. She writes the Global Perspectives column for EuroCosmetics magazine, is a former Editor of CosmeticsDesign, and is known globally for her ability to identify emerging trends, novel technologies, and true innovation in beauty. A PRODUCTION OF Cosmoprof Worldwide BolognaCosmoFactory is the first podcast from Cosmoprof Worldwide Bologna, taking its place among the best B2B podcasts serving the global beauty industry.   Cosmoprof Worldwide Bologna is the most important beauty trade show in the world. Dedicated to all sectors of the industry, Cosmoprof Worldwide Bologna welcomes over 250,000 visitors from 150 countries and regions and nearly 3,000 exhibitors to Bologna, Italy, each year. It's where our diverse and international industry comes together to build business relationships and to discover the best brands and newest innovations across consumer beauty, professional beauty, and the entire supply chain. The trade show includes a robust program of exclusive educational content, featuring  executives and key opinion leaders from every sector of the cosmetics, fragrance, and personal care industry. Cosmoprof Worldwide Bologna is the most important event of the Cosmoprof international network, with exhibitions in Asia (Hong Kong), the US (Las Vegas and Miami), India (Mumbai) and Thailand (Bangkok). Thanks to its global exhibitions Cosmoprof connects a community of more than 500,000 beauty stakeholders and 10,000 companies from 190 countries and regions. Learn more today at Cosmoprof.com 

Drs. Jonathan Ryder and Sarah Turbett discuss blood culture stewardship!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode of HIV unmuted, host Juan Michael Porter II sits down with Jeanne Marrazzo, the Director of the National Institute of Allergy and Infectious Diseases (NIAID), in a conversation that goes beyond the headlines and deep into the heart of HIV research and advocacy. Dr Marrazzo, a leader with decades of experience in infectious disease research, shares her inspiring journey from her roots in Scranton, Pennsylvania, to her groundbreaking work in HIV prevention and care. Through this intimate conversation, listeners will discover what drives Dr. Marrazzo's commitment to equity, diversity and community-centered research, and how her personal and professional experiences shape her vision for the future of HIV science. From the challenges of addressing global health inequities to the optimism surrounding new HIV prevention methods, Dr Marrazzo offers valuable insights into the importance of inclusive messaging, the power of collaboration, and why putting people first remains at the core of her mission. Tune in to hear how Jeanne Marrazzo plans to navigate the evolving landscape of global health as she leads NIAID into a new era, and why she believes that hope, innovation, and community are key to overcoming the ongoing challenges in the HIV response. Meet our guest: Jeanne Marrazzo   Jeanne Marrazzo, MD, MPH, FACP, FIDSA, is the Director of NIAID at the U.S. National Institutes of Health (NIH), where she oversees a USD 6.3 billion budget that supports research to advance understanding, diagnosis and treatment of infectious, immunologic and allergic diseases. She was previously the C. Glenn Cobbs Endowed Chair and Director of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine. She is a Fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021 to 2023, having served on the board since 2018. She researches the vaginal microbiome, sexually transmitted infections and HIV pre-exposure prophylaxis. She has had leadership roles in the NIH HIV Prevention Trials Network and the Infectious Diseases Clinical Research Consortium. She was a leading voice in communicating science during the COVID-19 pandemic.   Meet our host: Juan Michael Porter II  Juan Michael Porter II is a health journalist, HIV advocate, culture critic, educator and the host of HIV unmuted, the IAS podcast. He is the Senior Editor of TheBody.com and TheBodyPro – and the first person openly living with HIV to hold the position. Juan Michael's reportage combines data dives, personal narratives and policy analyses to address the real-world consequences of ever-shifting legislation on people's health outcomes. He has written for the Public Broadcasting Service, SF Chronicle, Philadelphia Inquirer, Christian Science Monitor, NY Observer, TDF Stages, Playbill, American Theatre, Time Out NY, Queerty, Anti-Racism Daily, Positively Aware, Documentary Magazine, SYFY Wire, Scholastic and Dance Magazine. 

This StAR episode features the CID State-of-the-Art Review on use of antimicrobials at the end of life.Our guest stars this episode are:Daniel Karlin (University of California Los Angeles, UCLA)Christine Pham (UCLA)Daisuke Furukawa (Stanford)Journal article link: Karlin D, Pham C, Furukawa D, et al. State-of-the-Art Review: Use of Antimicrobials at the End of Life. Clin Infect Dis. 2024;78(3):e27-e36. doi:10.1093/cid/ciad735Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/3/493/7596075From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on a comprehensive approach to vascular graft infection.Our guest stars this episode are:Hussam TabajaSupavit “Mac” ChesdachaiDaniel DeSimone(from Mayo Clinic, Rochester, Minnesota)Journal article link: Tabaja H, Chesdachai S, Shah AS, et al. Fostering Collaborative Teamwork-A Comprehensive Approach to Vascular Graft Infection Following Arterial Reconstructive Surgery. Clin Infect Dis. 2024;78(6):e69-e80. doi:10.1093/cid/ciae150Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/6/1391/7651000From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Unfortunately, there simply isn't a one-size-fits-all treatment protocol for patients infected with Lyme disease and/or co-infections. This is why it's critical for physicians treating Lyme disease to invest time with patients, thoroughly understand their medical history, and closely monitor symptoms and treatment response. With that in mind, there are currently two different treatment approaches for Lyme disease. The Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS) have each published their own set of evidence-based treatment guidelines. IDSA guidelines recommend a short course of antibiotics, typically 14 to 30 days. IDSA argues that the Borrelia burgdorferi bacteria do not persist in a patient beyond this timeframe and that lingering symptoms are the result of an ongoing immune response and not an active infection. It also cites scientific evidence claiming treatments beyond 30 days are ineffective, unnecessary, and even dangerous. IDSA physicians will stop treatment after 30 days, even if symptoms remain. They advise an additional 30 days of treatment recommended for patients with Lyme arthritis.  On the contrary, ILADS offers its own scientific data to show that a additional treatment with antibiotics is required to eradicate the bacteria. ILADS recognizes that a month of treatment may be sufficient for patients in the acute stage of Lyme disease, but in cases where the spirochete has disseminated and the disease has advanced, a 30-day treatment regimen is inadequate. ILADS guidelines recommend additional antibiotics until a patient's symptoms have been resolved. Treating Lyme disease in its advanced stage can be complicated based on the complexity of the organism itself, differences in each patient's immune system, the length of time infected, and the possible presence of other co-infections transmitted by the same tick. There are several choices in treating Lyme disease, which include oral, intravenous, and intramuscular antibiotic options. Other options may include sequential antibiotic therapy, higher doses of antibiotics, taking antibiotics for a longer period of time, a combination of antibiotics, retreatment, as well as diagnosing and treating co-infections. Some specific antibiotics used in treating Lyme disease are doxycycline, minocycline, amoxicillin, cefuroxime, azithromycin, and clarithromycin. Other tests include measures of blood counts, chemistries, liver function tests, ANA, dsDNA, RF, TSH, free T3, free T4, ESR may be helpful at ruling out other conditions.  Referral to specialist might help to rule out other conditions.  I find shared decision with my patient helpful. I also find follow-up helpful to assess my patient's response to treatment to rule out other conditions. There are additional protocols that may also aid in treating Lyme disease, such as avoiding alcohol, simple and processed sugars, exercising as tolerated, counseling for a Jarisch-Herxheimer reaction, managing symptoms, monitoring and reducing the risk of an adverse event, and reducing stress. However, there is a chance of side effects such as Clostridium difficile-associated diarrhea (CDAD). Probiotic have been prescribed with the hope of reducing the risk of developing CDAD.   

Welcome! Today, we're exploring the key milestones in Lyme disease research and treatment.I had a 57-year-old patient who remained chronically ill after being diagnosed and treated for Lyme disease. He didn't realize that a persistent tick-borne infection could explain his chronic illness. He was treated with a combination of azithromycin and atovaquone for the persistent infection, and today, he is doing well.He was surprised that, despite the milestones in Lyme disease research, he wasn't aware that a persistent infection could lead to his chronic illness. So, let's take a closer look at these milestones.1. 1977: Discovery of Lyme DiseaseOur story begins in 1977 in Lyme, Connecticut. A cluster of children and adults were diagnosed with what was initially thought to be juvenile rheumatoid arthritis. This event marked the identification of Lyme disease as a distinct illness and the start of modern Lyme disease awareness."2. 1982: Discovery of the Bacterium Responsible for Lyme DiseaseIn 1982, Dr. Willy Burgdorfer identified Borrelia burgdorferi, the bacterium responsible for Lyme disease. This discovery was a major milestone, enabling more precise identification and treatment of the disease. 3. 1990: Recognition of Chronic Lyme DiseaseBy 1990, chronic Lyme disease, with its long-term and persistent symptoms, was officially recognized. This led to more comprehensive treatment protocols and increased awareness of the disease's chronic nature.4. 1995: Discovery of Babesia microtiIn 1995, Babesia microti was identified as a co-infection transmitted by the same ticks that carry Lyme disease. This highlighted the complexity of tick-borne illnesses and the need for integrated treatment approaches. 5. 2000: Publication of IDSA and ILADS GuidelinesThe year 2000 saw the publication of treatment guidelines by both the Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS). These guidelines showcased different approaches to treating Lyme disease, marking another significant milestone. 6. Ongoing Research and Future Milestones Research is ongoing, and we look forward to future milestones that could lead to breakthroughs in diagnosis and treatment. Studies on biofilms, persisters, and tick-borne co-infections may enable doctors to develop treatment plans that significantly improve patient outcomes.ConclusionUnderstanding these milestones helps us appreciate the progress made in the fight against Lyme disease. With continued research and dedication, we move closer to effective management and potential cures. Thank you for watching, and stay tuned for more insights on Lyme disease." 

This StAR episode features the CID State-of-the-Art Review on Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Our guest stars this episode are:Daniel Chastain (University of Georgia College of Pharmacy)Megan Spradlin (University of Colorado)Hiba Ahmad (University of Colorado)Andrés F Henao-Martínez (University of Colorado)Journal article link: Chastain DB, Spradlin M, Ahmad H, Henao-Martínez AF. Unintended Consequences: Risk of Opportunistic Infections Associated With Long-term Glucocorticoid Therapies in Adults. Clin Infect Dis. 2024;78(4):e37-e56. doi:10.1093/cid/ciad474Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/4/811/7643625From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on ##.Our guest stars this episode are:Arsheena Yassin (Robert Wood Johnson University Hospital)Mariya Huralska (Robert Wood Johnson University Hospital)Journal article link: Yassin A, Huralska M, Pogue JM, Dixit D, Sawyer RG, Kaye KS. State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms. Clin Infect Dis. 2023;77(9):e46-e56. doi:10.1093/cid/ciad499Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/9/1223/7408674From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Maxime Billick and Isaac Bogoch from the University of Toronto discuss the buffet of options available for HIV biomedical prevention!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This is episode 33 of the Love, Hope, Lyme podcast. Fred Diamond's popular book, "Love, Hope, Lyme: What Family Members, Partners, and Friends Who Love a Chronic Lyme Survivor Need to Know" offers those who love someone with persistent or chronic Lyme ideas and tips to support this beloved person. It also helps Lyme survivors know how to ask for support. On today's episode, Fred interviews patient-centered healthcare advocate Bruce Alan Fries. It's incredible that Lyme and other tick-borne diseases have political implications. For scores, entities such as the CDC and the Infectious Diseases Society of America (IDSA) refused to acknowledge that chronic Lyme disease even existed and recommended minimal treatment protocols that, in many cases, did not even come close to treating the diseases. Bruce discussed some of the political initiatives he created or participated in to bring more government awareness of these troubling diseases. If someone you love has been afflicted with Lyme disease, watch this podcast now. If you have Lyme disease, listen for ways to get the support you need. The e-version of Fred's book is always free for Lyme survivors. Just reach out to Fred on Facebook or LinkedIn. The print copy can be ordered at https://a.co/d/ifi9Wne.

This StAR episode features the CID State-of-the-Art Review on Staphylococcus aureus bacteremia - controversies in clinical practice.Our guest stars this episode are: Daniel Minter (UCSF)Sarah Doernberg (UCSF)Journal article link: Minter DJ, Appa A, Chambers HF, Doernberg SB. Contemporary Management of Staphylococcus aureus Bacteremia-Controversies in Clinical Practice. Clin Infect Dis. 2023 Nov 30;77(11):e57-e68. doi: 10.1093/cid/ciad500. PMID: 37950887.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/11/1489/7453594From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Maria Gabriela Segura, Misti Ellsworth, and Michael Chang from UTHealth Houston McGovern Medical School and Children's Memorial Hermann Hospital chat about an unusual pediatric case of fever of unknown origin.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on neurosyphilis.Our guest star this episode is Dr. Matthew Hamill (Johns Hopkins University)Journal article link: Hamill MM, Ghanem KG, Tuddenham S. State-of-the-Art Review: Neurosyphilis. Clin Infect Dis. 2024 May 15;78(5):e57-e68. doi: 10.1093/cid/ciad437. PMID: 37593890.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/5/1085/7672813From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Happy World Environment Day (June 5 2024)! Our guests celebrate by discussing sustainability in healthcare and infectious diseases. Join Drs. Shreya Doshi, Preeti Jaggi, Pam Lee, and Shira Abeles as they raise awareness about the ways ID professionals can help reduce the negative environmental impact of the way we provide healthcare to our patients!Here is the JPIDS/OFID Supplement Introduction from Drs. Doshi and Jaggi: Healthcare Environmental Sustainability Through an Infectious Diseases LensThe second article mentioned is: Healthcare Sustainability to Address Climate Change, Call for Action to the Infectious Diseases CommunityThe Sustainabil-ID group mentioned in the podcast can be found on Twitter/X @sustain-ID as well as via email at sustainabilityiddocs@gmail.comEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

In this episode,  hosts Drs. Temara Hajjat and Peter Lu talk to Dr. Maria Oliva-Hemker about diagnosing and managing Clostridioides difficile (C. diff) in children who have inflammatory bowel disease (IBD). Dr. Oliva-Hemker is the Director of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition and the Stermer Family Professor for Pediatric IBD at the Johns Hopkins University School of Medicine. She is also the Vice Dean for Faculty and the Mary Wallace Stanton Professor for Faculty Affairs. Learning Objectives:Learn how to diagnose Clostridioides difficile, particularly when there is concern about a new IBD diagnosis.Learn how to manage C. diff infection in a patient with known IBD.Learn how to manage recurrent and refractory C. diff infection in a patient with IBD.Link: Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal DiseasesACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile InfectionsSupport the Show.This episode is eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Step into the role of a hospital epidemiologist managing a measles outbreak response with Drs. Palak Patel, Emily Landon, and David Zhang from the University of Chicago!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on acute encephalitis.Our guest stars this episode are: Karen Bloch (Adult ID physician at Vanderbilt University Medical Center)Carol Glaser (Pediatric ID physician at California Department of Public Health)David Gaston (Adult ID physician and clinical microbiologist at Vanderbilt University Medical Center)Arun Venkatesan (Neurologist at Johns Hopkins University)Journal article link: Bloch KC, Glaser C, Gaston D, Venkatesan A. State of the Art: Acute Encephalitis. Clin Infect Dis. 2023;77(5):e14-e33. doi:10.1093/cid/ciad306Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/5/669/7269079From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on periprosthetic joint infections.Our guest stars this episode are: Sandra Nelson (ID physician at Massachusetts General Hospital)Jodian Pinkney (ID physician at Massachusetts General Hospital)Antonia Chen (Orthopedic surgeon at Brigham and Women's Hospital)Aaron Tande (ID physician at Mayo Clinic)Journal article link: Nelson SB, Pinkney JA, Chen AF, Tande AJ. Periprosthetic Joint Infection: Current Clinical Challenges. Clin Infect Dis. 2023;77(7):e34-e45. doi:10.1093/cid/ciad360Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/7/939/7289507From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review: Frame Shift – Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized with Infections.Our guest stars this episode are: Dr. Kinna Thakarar (ID and Addiction Medicine physician at MaineHealth/Tufts University School of Medicine)Dr. Ayesha Appa (ID and Addiction Medicine physician at University of California San Francisco, UCSF)Chastity Tuell (Harm reductionist and Washington County Program Director for Maine Access Points)Journal article link: Thakarar K, Appa A, Abdul Mutakabbir JC, Goff A, Brown J 3rd, Tuell C, Fairfield K, Wurcel A. Frame Shift: Focusing on Harm Reduction and Shared Decision Making for People Who Use Drugs Hospitalized With Infections. Clin Infect Dis. 2024 Feb 17;78(2):e12-e26. doi: 10.1093/cid/ciad664. PMID: 38018174.Journal companion article - Executive summary link: https://academic.oup.com/cid/article/78/2/233/7453720From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

This StAR episode features the CID State-of-the-Art Review on evaluation and management of diabetes-related foot infections.Our guest stars this episode are:Dr. Meghan Brennan (ID physician at University of Wisconsin)Dr. Marcos Schechter (ID physician at Emory University)Dr. Tze-Woei Tan (Vascular surgeon at University of Southern California)Dr. David Armstrong (Podiatric surgeon at University of Southern California)Journal article link: Nicolas W Cortes-Penfield, David G Armstrong, Meghan B Brennan, Maya Fayfman, Jonathan H Ryder, Tze-Woei Tan, Marcos C Schechter, Evaluation and Management of Diabetes-related Foot Infections, Clinical Infectious Diseases, Volume 77, Issue 3, 1 August 2023, Pages e1–e13, https://doi.org/10.1093/cid/ciad255Journal companion article - Executive summary link: https://academic.oup.com/cid/article/77/3/335/7242512From Clinical Infectious DiseasesEpisodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Paul Sax, Tara Vijayan, and Allan Tunkel join Febrile to chat about the debut of a new series called “StAR”!! These upcoming episodes will highlight the outstanding Clinical Infectious Diseases (CID) journal State-of-the-Art Reviews (StAR), which cover common clinical topics that ID clinicians encounter. Learn more about the creation of these articles from these CID editors before we kick off 4 back-to-back episodes!!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Jack Flores and Madan Kumar chat about the nuances of Kawasaki disease (and provide a mystery riddle!! solution in the Consult Notes!)Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Sumanth Cherukumilli, Emma Mohr, and Paul Spearman join for a live Febrile recording at the St. Jude / PIDS Pediatric Infectious Diseases Research Conference in Memphis, TN. They cover some learning points about early onset neonatal sepsis and chat about career development. Thank you to the conference organizers for the opportunity!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

Drs. Genevieve Martin, Catherine Marshall, and Bart Currie from the Royal Darwin Hospital share their approach to Burkholderia pseudomallei aka melioidosis!Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA). Audio editing/mixing provided by Bentley Brown.

Drs. Michael Moran and Swapnil Lanjewar from the University of Wisconsin-Madison walk through a case and their approach to the common ID consult for fever and rash.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA). Audio editing/mixing by Bentley Brown.

Future physician Sophie Samson, Dr. Kristen Bastug, and Dr. Beth Thielen discuss a case of a 7 year old girl who presented with new onset seizure, headache, and fever in Minnesota.Episodes | Consult Notes | Subscribe | Twitter | Merch | febrilepodcast@gmail.comFebrile is produced with support from the Infectious Diseases Society of America (IDSA)

• Background of Dr. John Lambert: Dr. John Lambert was born in Scotland, parents immigrated to America, thus obtaining an American education. Returned to the UK in 1999 before settling in Dublin, Ireland shortly after. Working as an infectious disease and Lyme specialist for 18 years. • Education & Professional Journey: College in Kalamazoo, Michigan. Attended University of Sterling in Scotland. Expressed the challenges of transitioning between countries. Always had an inclination towards medical school, initially interested in tropical medicine. Work experience in Haiti at a Mission Hospital. • Infectious Disease Conferences & Updates: Attended a recent Infectious Disease Society of America (IDSA) conference in Boston. Updates on Lyme, coronavirus, HIV/AIDS, tropical medicine, and vaccine developments. • Intricacies of Infectious Diseases: The dual excitement of diagnosing and treating infectious diseases, like Lyme disease. The significance of monitoring patients. Emphasis on evidence-based treatments and results. • Publications and Expertise: Dr. Lambert's 25+ publications. The importance of verifying experts through PubMed searches. The challenges of diagnostics in the Lyme community. • Defining Lyme Disease: Tick Boot Camp provides Tick Boot Camp's definition of Lyme disease. Dr. Lambert's perspective on the definition and the polymicrobial nature of Lyme. • Treatment Guidelines and Controversies: Irish guidelines on Lyme treatment. The debate on chronic Lyme and the skepticism surrounding it. • Immune System Implications: Lyme disease's dual impact on the immune system: immune suppression and potential autoimmune reactions. Discussion on the potential similarities and differences between Lyme disease and other conditions like long COVID. • Diagnostic Tools and Collaborations: Collaboration with Dr. Samiy from the University of North Carolina State. Newer diagnostic tools and their significance. • Treatment Modalities and Approaches: The utilization of LDN (Low Dose Naltrexone) and NAC (N-acetyl cysteine). The importance of maintaining a healthy microbiome. Dr. Lambert's collaborative approach, working alongside herbalists. • Final Thoughts: Emphasizing the bacterial nature of Lyme disease. The importance of timely diagnosis and appropriate treatment.

On this episode, we review the 2023 Hepatitis C Guidance that was recently published by the Infectious Diseases Society of America (IDSA) and the American Association for the Study of Liver Diseases (AASLD). We discuss the pre-treatment work-up, various treatment options, and drug-drug interactions/clinical pearls for the most commonly used direct-acting antivirals.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! We want to give a big thanks to our sponsor, High-Powered Medicine. HPM is a book/website database of summaries for over 150 landmark clinical trials. You can get a copy of HPM, written by Dr. Alex Poppen, PharmD, at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx  This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.

Episode 155: Diabetic Foot Infection GuidelinesFuture Dr. Perez presents the updates on lung cancer screening by the American Cancer Society. Future Dr. Danusantoso explains the classification, diagnosis, and treatment of diabetic foot infections according to the guidelines published by the International Working Group on the Diabetic Foot (IWGDF). Dr. Arreaza adds comments and anecdotes.  You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Intro: Lung cancer screening update.Written by Luz Perez, MSIII, Ross University School of Medicine. Editing by Hector Arreaza, MD.Hello, my name is Luz Perez and today I will talk about lung cancer screening.As a reminder, lung cancer is the top cause of cancer-related death in men and women worldwide. In the United States, lung cancer causes the death of about 154,000 people each year[4]. Smoking is the most significant risk factor for developing lung cancer, a risk that directly correlates to how much and how long a person has smoked[2]. Despite the efforts to decrease lung cancer-related deaths, which include screening of patients at risk and counseling on smoking cessation, many patients go undiagnosed in part because lung cancer can be asymptomatic but also because many people at risk did not meet the criteria for screening, according to previous guidelines… BUT On November 1, 2023, the American Cancer Society updated its guidelines for lung cancer screening to decrease mortality by lung cancer in the US. The updated lung cancer screening guidelines were published in November, which is Lung Cancer Awareness Month. This guideline aims to expand eligibility criteria for lung cancer screening. Previously, the guidelines covered people only between the ages of 55-74 who were current smokers or had quit within the past 15 years and had a 30 or more pack-year smoking history[3].The new guidelines recommend annual screening with low-dose CT (LDCT) scan for people who are 50-80 years old who are current or former smokers and who have a 20 or more pack-year of smoking history [1]. This change means that about 5 million people who would previously not qualify for screening are now eligible for this potentially lifesaving screening exam.Additionally, the American Cancer Society emphasizes the significance of shared decision-making between patients and healthcare providers on lung cancer screening and smoking cessation. This includes ways to help patients stop smoking by providing counseling and interventions including medications. For patients who are eligible for screening, having a full discussion of the lung cancer screening process including the purpose of the procedure, risks and benefits of low-dose CT, and recommendations from other organizations, is key in the shared decision-making process[1]. Perhaps, the most important step in the implementation of these new guidelines is ensuring that medical professionals talk to their patients about them and make them aware of the importance of screening for lung cancer. In this way, we can reduce mortality and other consequences of this devastating disease. Written by Maria Danusantoso, MSIV, Ross University School of Medicine. Editing by Hector Arreaza, MD.Update to Guidelines for Treatment of Diabetic Foot InfectionsIntroductionIn October 2023, the International Working Group on the Diabetic Foot (IWGDF) and the Infectious Disease Society of America (IDSA) collaborated and published an update to the 2019 guideline on the diagnosis and management of infections of the foot in persons with diabetes mellitus.The present guidelines include a list of 25 recommendations for diagnosis and management and clinically useful figures and tables including a treatment algorithm, a classification system for defining diabetic foot infections, and empirical antibiotic therapy according to clinical presentation and microbiological data.The goal of this episode is not to provide an exhaustive review of the updated guidelines and algorithms but to highlight what I believe are the most important recommendations. I hope this brief presentation is viewed as an introduction and that this encourages you, the listener, to independently read the guidelines in full and implement them into your own clinical practice.Wound Colonization Versus Wound InfectionBefore jumping into some of the recommendations, I want to take some time to discuss briefly how to classify diabetic foot infections. Most clinicians, including myself, will see a patient with diabetes with a foot ulcer or wound and want to treat it with antibiotics or admit the patient to the hospital. However, the updated guidelines propose that antibiotics and/or admission are not always indicated. For clinicians, there needs to be an awareness that wound colonization and wound infection are not the same. Wound colonization by bacteria is defined by the presence of bacteria on a wound surface without evidence of invasion of the host tissues. Colonization, then, can be considered a constant phenomenon as we live in a bacteria-filled world. Comment: If we culture our intact skin, we may find pathogens, that's why wound cultures even if they are positive, do not indicate there is infection. Tell us about infection.In contrast, wound infection is a disease state caused by the invasion and multiplication of microorganisms in host tissues that induce an inflammatory response in the host, usually followed by tissue damage. Therefore, since all wounds are colonized – often with potentially pathogenic microorganisms – we cannot define wound infection using only the results of wound cultures. Instead, diabetic foot infections are a clinical diagnosis based on the presence of manifestations of an inflammatory process involving a foot wound located below the malleoli. These signs and symptoms of inflammation may be masked in persons with diabetes especially if they have some level of baseline peripheral neuropathy, peripheral artery disease, or immune dysfunction.Classification of Diabetic Foot Infections.To assist with the classification of diabetic foot infections, the updated guidelines include a table for defining the presence and severity of an infection of the foot in a person with diabetes. Again, diabetic foot infections are a clinical diagnosis, and the clinical classification of infection can be described as: 1) uninfected, 2) mild, 3) moderate +/- O if osteomyelitis is present, 4) severe +/- O if osteomyelitis is present. Uninfected has no systemic or local symptoms or signs of infection. Mild infection is when at least two of the following are present: local swelling or induration, erythema between 0.5-2 cm around the wound in any direction, local tenderness or pain, local increased warmth, purulent discharge, and there is no other cause of an inflammatory response of the skin present (e.g., trauma, gout, acute Charcot neuro-arthropathy, fracture, thrombosis, or venous stasis).Moderate infection is without systemic manifestations and involves erythema extending 2 cm or more from the wound margin and/or involves tissue deeper than skin and subcutaneous tissues (e.g., tendon, muscle, joint, and bone) +/- the presence of osteomyelitis. The surrounding erythema and the depth of wound are key element in the classification of the wounds. Severe infection is associated with systemic manifestations and meets systemic inflammatory response syndrome (SIRS) criteria as manifested by 2 or more of the following: temperature below 36°C or above 38°C, heart rate greater than 90 beats per minute, respiratory rate greater than 20 breaths per minute, white blood cell count greater than 12,000/mm3 or greater than 10% immature (band) forms +/- presence of osteomyelitis. Features of Osteomyelitis on Plain X-RayWe have mentioned osteomyelitis quite a few times in this episode, so what are some ways we can diagnose osteomyelitis? Most commonly, osteomyelitis is diagnosed via imaging either with plain X-rays  or MRI. When looking at plain X-rays, there are a few features that are characteristic of diabetes-related osteomyelitis of the foot of which we should be aware regardless of our status as radiologists. Some of these features include bone sclerosis with or without erosion, abnormal soft tissue density or gas density in the subcutaneous fat, or new or evolving radiographic features on serial images spaced several weeks apart such as loss of bone cortex, focal demineralization, periosteal reaction or elevation. Changes in x-ray may be a late finding and indicate that the osteomyelitis is established.General Treatment Recommendations for Diabetic Foot InfectionsIn the updated guidelines, recommendation 11 states to not treat clinically uninfected foot ulcers with systemic or local antibiotic therapy when the goal is to reduce the risk of new infection or to promote ulcer healing. As previously said, diabetic foot infections are a clinical diagnosis. So if clinically the wound does not meet criteria to be classified as a mild, moderate, or severe infection, this recommendation proposes that no antibiotic treatment is the best treatment so as not to expose patients to potentially unnecessary and harmful treatment and to not promote antibiotic resistance in patients, which would potentially make treating diabetic foot infections more challenging in the future. We still want to very closely monitor the wound every 2-7 days and promote wound healing with pressure offloading, keeping the wound and the surrounding skin clean and dry, and other non-antibiotic management for local wound care.What are some common bacteria?.When it is indicated to treat diabetic foot infections per the guidelines, recommendation 14 states to target aerobic gram positive pathogens only for people with a mild diabetes related foot infection. These pathogens include beta hemolytic streptococci and Staphylococcus aureus including methicillin-resistant strains if indicated. Additionally, recommendation 15 advises not to empirically target antibiotic therapy against Pseudomonas aeruginosa in cases of diabetes-related foot infection in temperate climates. However, it is appropriate to use empirical treatment of P. aeruginosa if it has been isolated from cultures of the affected site within the previous few weeks or in a person with moderate or severe infection who resides in tropical/subtropical climates.Antibiotic Treatment Duration RecommendationThe final recommendation we have time to discuss in this episode is regarding antibiotic treatment duration. For mild infections, oral antibiotics (such as cephalexin or Bactrim) for a duration of 1-2 weeks is appropriate. However, if the infection is improving but is extensive and is resolving slower than expected or if the patient has severe peripheral artery disease, it is reasonable to consider extending treatment for up to 3-4 weeks.For moderate or severe infections without osteomyelitis, a total treatment duration of 2-4 weeks is recommended starting initially with IV antibiotics before transitioning to oral antibiotics. Antibiotic selection will depend on multiple factors, such as recent antibiotic use, or MRSA risk factors. For example, if the patient took antibiotics recently, they could receive Zosyn® and ceftriaxone. If osteomyelitis is present, antibiotic treatment duration can be anywhere from 2 days to 6 weeks depending on the amount of source control achieved. Ideally, we should wait to have bone resection before giving antibiotics, but we know that antibiotics are given promptly in the ER.In the cases of a resected infected bone or joint (when complete source control is achieved), a duration of 2-5 days is recommended, starting with IV antibiotics before transitioning to oral antibiotics. If there is minor amputation of the infected foot but there remains a positive wound culture or positive margins are seen on pathology (inflammatory cells are seen at the proximal margin of the amputated section), a 3-week antibiotic treatment duration is recommended, again starting with IV before transitioning to oral antibiotics.For diabetes-related foot osteomyelitis without bone resection or amputation, a 6-week course of antibiotics is recommended, again initially with IV antibiotics before transitioning to oral. In all the situations where there is a transition from IV to oral antibiotics, this transition may only occur once there are clinical signs of improvement, for example, improving erythema surrounding the wound, resolution of tenderness or purulent drainage, or SIRS criteria is no longer met.Summary: For more details regarding the 2023 update to the guidelines on the diagnosis and treatment of foot infection in persons with diabetes, please refer to the complete guidelines which can be accessed on the IWGDF Guidelines website and via the citations listed in the References. As a reminder, this podcast episode is not an exhaustive review of the guidelines, but, instead, a brief introduction to some of the recommendations. Thank you for listening and I hope you learned something new!_____________________________Conclusion: Now we conclude episode number 155 “Diabetic foot guidelines.” Future Dr. Perez started this episode with an introduction about the new guidelines to screen for lung cancer, then future Dr. Danusantoso gave an excellent summary about the classification and treatment of diabetic foot infections. Our patients with diabetes must have foot self-awareness and report any concerns to their family physicians or podiatrists so they can get prompt treatment.This week we thank Hector Arreaza, Luz Perez, and Maria Danusantoso. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:McDowell, Sandy, New Lung Cancer Screening Guideline Increases Eligibility. American Cancer Society, published on November 1, 2023, Cancer.org. https://www.cancer.org/research/acs-research-news/new-lung-cancer-screening-guidelines-urge-more-to-get-ldct.htmlWolf AMD, Oeffinger KC, Shih TY, et al. Screening for lung cancer: 2023 guideline update from the American Cancer Society [published online ahead of print, 2023 Nov 1]. CA Cancer J Clin. 2023;10.3322/caac.21811. doi:10.3322/caac.21811. Link: https://pubmed.ncbi.nlm.nih.gov/37909877/Moniuszko, Sara. Lung cancer screening guidelines updates by American Cancer Society to include more people. CBS News, updated on November 3, 2023. https://www.cbsnews.com/news/lung-cancer-screening-guideline-american-cancer-society-update/Deffebach, M. E., & Humphrey, L. (2023). Screening for lung cancer. UpToDate. Retrieved November 6, 2023, UpToDate. https://www.uptodate.com/contents/screening-for-lung-cancerÉric Senneville, Zaina Albalawi, Suzanne A van Asten, Zulfiqarali G Abbas, Geneve Allison, Javier Aragón-Sánchez, John M Embil, Lawrence A Lavery, Majdi Alhasan, Orhan Oz, Ilker Uçkay, Vilma Urbančič-Rovan, Zhang-Rong Xu, Edgar J G Peters, IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023), Clinical Infectious Diseases, 2023; ciad527, https://doi.org/10.1093/cid/ciad527Senneville, Éric et al. 2023. “IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Foot Infection in Persons with Diabetes.” IWGDF Guidelines. Retrieved November 6, 2023 (https://iwgdfguidelines.org/wp-content/uploads/2023/07/IWGDF-2023-04-Infection-Guideline.pdf). Royalty-free music used for this episode: Gushito, “Gista Mista”, downloaded on November 16th, 2023, from https://www.videvo.net/ 

Neste episódio, você ficará por dentro do que foi abordado no IDWeek, fórum anual promovido pela Infectious Diseases Society of America (IDSA). Realizado em Boston, nos Estados Unidos, entre os dias 11 e 15 de outubro de 2023, o congresso teve como temas centrais o PEPFAR (Plano de Emergência do Presidente dos EUA para combater à AIDS), muita discussão sobre o HIV e outras infecções sexualmente transmissíveis, além do que podemos esperar para os novos guidelines da IDSA. Escute agora! Confira esse e outros posts no Portal PEBMED e siga nossas redes sociais! Facebook Instagram Linkedin Twitter

Michelle Berryman, a Georgia Institute of Technology graduate, boasts an impressive and diverse design portfolio that includes exhibits, events, interiors, and user interfaces for various products. She has collaborated with renowned clients such as HP, Philips, Nike, and Siemens and is a founding Principal of Echo Visualization, LLC (EchoViz) in Atlanta. Michelle has held significant positions in the Industrial Designers Society of America (IDSA) and the International Council of Societies of Industrial Design (Icsid). Her passion for industrial design was ignited during high school when she witnessed her terminally ill mother benefit from assistive products, emphasizing the importance of user experience in design.In 2000, Michelle pursued her Master's at Georgia Tech, focusing on merging environment design with interactive media. Her research spanned hands-free proximity photography and assistive product interface design, culminating in a thesis on a heart rate monitor and lifestyle management tool for cardiac patients. During her academic journey, she was recognized as "Teacher of the Year" by her peers and faculty. Post-graduation, Michelle worked with the Georgia Tech Research Institute (GTRI), concentrating on product interface design and developing systems for rapid prototyping interfaces. Her endeavors also included designing assistive interfaces compliant with U.S. government regulations.In 2002, Michelle co-founded EchoViz, an interaction design & user experience consultancy. EchoViz offers many services, from business analysis and digital strategy to graphic design and software development, always aiming to create an emotional connection with users. Since its inception, EchoViz has garnered multiple design awards and was acquired by THINK in 2012, where Michelle now serves as the Director of UX. Michelle has received numerous accolades throughout her career, including being named one of the “10 Innovators You Should Know” in 2005 and a nominee for the Women in Technology (WIT) award in 2006.

Director of the Center for Infectious Disease Research and Policy at the University of Minnesota, Dr. Michael Osterholm, joins Zerlina on the show to discuss the state of the COVID-19 Pandemic.Dr. Osterholm is Regents Professor, McKnight Presidential Endowed Chair in Public Health, the director of the Center for Infectious Disease Research and Policy (CIDRAP), Distinguished Teaching Professor in the Division of Environmental Health Sciences, School of Public Health, a professor in the Technological Leadership Institute, College of Science and Engineering, and an adjunct professor in the Medical School, all at the University of Minnesota.https://twitter.com/mtosterholmIn November 2020, Dr. Osterholm was appointed to President-elect Joe Biden's 13-member Transition COVID-19 Advisory Board. From June 2018 through May 2019, he served as a Science Envoy for Health Security on behalf of the US Department of State. He is also on the Board of Regents at Luther College in Decorah, Iowa.He is the author of the New York Times best-selling 2017 book, Deadliest Enemy: Our War Against Killer Germs, in which he not only details the most pressing infectious disease threats of our day but lays out a nine-point strategy on how to address them, with preventing a global flu pandemic at the top of the list.In addition, Dr. Osterholm is a member of the National Academy of Medicine (NAM) and the Council of Foreign Relations. In June 2005 Dr. Osterholm was appointed by Michael Leavitt, Secretary of the Department of Health and Human Services (HHS), to the newly established National Science Advisory Board on Biosecurity. In July 2008, he was named to the University of Minnesota Academic Health Center's Academy of Excellence in Health Research. In October 2008, he was appointed to the World Economic Forum Working Group on Pandemics.From 2001 through early 2005, Dr. Osterholm, in addition to his role at CIDRAP, served as a Special Advisor to then–HHS Secretary Tommy G. Thompson on issues related to bioterrorism and public health preparedness. He was also appointed to the Secretary's Advisory Council on Public Health Preparedness. On April 1, 2002, Dr. Osterholm was appointed by Thompson to be his representative on the interim management team to lead the Centers for Disease Control and Prevention (CDC). With the appointment of Dr. Julie Gerberding as director of the CDC on July 3, 2002, Dr. Osterholm was asked by Thompson to assist Dr. Gerberding on his behalf during the transition period. He filled that role through January 2003.Previously, Dr. Osterholm served for 24 years (1975-1999) in various roles at the Minnesota Department of Health, the last 15 as state epidemiologist. He has led numerous investigations of outbreaks of international importance, including foodborne diseases, the association of tampons and toxic shock syndrome, and hepatitis B and HIV in healthcare settings.Dr. Osterholm was the principal investigator and director of the NIH-supported Minnesota Center of Excellence for Influenza Research and Surveillance (2007-2014) and chaired the Executive Committee of the Centers of Excellence Influenza Research and Surveillance network.Dr. Osterholm has been an international leader on the critical concern regarding our preparedness for an influenza pandemic. His invited papers in the journals Foreign Affairs, the New England Journal of Medicine, and Nature detail the threat of an influenza pandemic before the recent pandemic and the steps we must take to better prepare for such events. Dr. Osterholm has also been an international leader on the growing concern regarding the use of biological agents as catastrophic weapons targeting civilian populations. In that role, he served as a personal advisor to the late King Hussein of Jordan. Dr. Osterholm provides a comprehensive and pointed review of America's current state of preparedness for a bioterrorism attack in his New York Times best-selling book, Living Terrors: What America Needs to Know to Survive the Coming Bioterrorist Catastrophe.The author of more than 315 papers and abstracts, including 21 book chapters, Dr. Osterholm is a frequently invited guest lecturer on the topic of epidemiology of infectious diseases. He serves on the editorial boards of nine journals, including Infection Control and Hospital Epidemiology and Microbial Drug Resistance: Mechanisms, Epidemiology and Disease, and he is a reviewer for 24 additional journals, including the New England Journal of Medicine, the Journal of the AmericanMedical Association, and Science. He is past president of the Council of State and Territorial Epidemiologists (CSTE) and has served on the CDC's National Center for Infectious Diseases Board of Scientific Counselors from 1992 to 1997. Dr. Osterholm served on the IOM Forum on Microbial Threats from 1994 through 2011. He has served on the IOM Committee on Emerging Microbial Threats to Health in the 21st Century and the IOM Committee on Food Safety, Production to Consumption, and he was a reviewer for the IOM Report on Chemical and Biological Terrorism. As a member of the American Society for Microbiology (ASM), Dr. Osterholm has served on the Committee on Biomedical Research of the Public and Scientific Affairs Board, the Task Force on Biological Weapons, and the Task Force on Antibiotic Resistance. He is a frequent consultant to the World Health Organization (WHO), the National Institutes of Health (NIH), the Food and Drug Administration (FDA), the Department of Defense, and the CDC. He is a fellow of the American College of Epidemiology and the Infectious Diseases Society of America (IDSA).Dr. Osterholm has received numerous honors for his work, including an honorary doctorate from Luther College; the Pump Handle Award, CSTE; the Charles C. Shepard Science Award, CDC; the Harvey W. Wiley Medal, FDA; the Squibb Award, IDSA; Distinguished University Teaching Professor, Environmental Health Sciences, School of Public Health, UMN; and the Wade Hampton Frost Leadership Award, American Public Health Association. He also has been the recipient of six major research awards from the NIH and the CDC.

This week, Marianna sits down with John Faragon to talk about ID Week, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS), and the Society of Infectious Diseases Pharmacists (SIDP), which took place in October 2022. Learn all about what happened in this episode. --Help us track the number of listeners our episode gets by filling out this brief form!  (https://www.e2NECA.org/?r=DDT4457) 

Lyme disease is the most common tick-borne disease in the US that can present in three different stages. Diagnosis is through a combination of a thorough history, review of systems, physical exam, as well as a two-tier serologic testing. Former Pediatric resident, Dr. James Davis, joins Associate Professor of Pediatrics, Dr. Susan Goldberg, to discuss the evaluation and management of Lyme Disease in the pediatric population. After listening to this podcast, learners should be able to: Recognize common presenting signs and symptoms of Early Localized, Early Disseminated, and Late Lyme disease from a patient history and physical examination Determine whether a patient meets clinical diagnostic criteria and, if not, which lab tests are appropriate for diagnosis of Lyme disease Appropriately prescribe the correct antibiotic choice and duration for patients, depending on variation of Lyme disease and accompanying symptoms Accurately and effectively instruct patients in prevention strategies for tick bites and Lyme disease Special thanks to Dr. Ingrid Camelo, Dr. Rebecca Yang and Dr. Jacob Eichenberger who peer reviewed today's episode. FREE CME Credit (requires free sign-up): https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=11411  References: Rodino KG, Theel ES, Pritt BS. Tick-Borne Diseases in the United States. Clin Chem. 2020 Apr 1;66(4):537-548. doi: 10.1093/clinchem/hvaa040. PMID: 32232463. Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG, Baldwin K, Bannuru RR, Belani KK, Bowie WR, Branda JA, Clifford DB, DiMario FJ, Halperin JJ, Krause PJ, Lavergne V, Liang MH, Meissner HC, Nigrovic LE, Nocton JJJ, Osani MC, Pruitt AA, Rips J, Rosenfeld LE, Savoy ML, Sood SK, Steere AC, Strle F, Sundel R, Tsao J, Vaysbrot EE, Wormser GP, Zemel LS. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021 Jan 23;72(1):e1-e48. doi: 10.1093/cid/ciaa1215. PMID: 33417672. Eddens T, Kaplan DJ, Anderson AJM, Nowalk AJ, Campfield BT. Insights From the Geographic Spread of the Lyme Disease Epidemic. Clin Infect Dis. 2019 Jan 18;68(3):426-434. doi: 10.1093/cid/ciy510. PMID: 29920580; PMCID: PMC6336907. Sundheim KM, Levas MN, Balamuth F, Thompson AD, Neville DN, Garro AC, Kharbanda AB, Monuteaux MC, Nigrovic LE. Seasonality of Acute Lyme Disease in Children. Trop Med Infect Dis. 2021 Nov 9;6(4):196. doi: 10.3390/tropicalmed6040196. PMID: 34842846; PMCID: PMC8628899. 2021. "Lyme Disease (Lyme Borreliosis, Borrelia burgdorferi sensu lato Infection)", Red Book: 2021–2024 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics, David W. Kimberlin, MD, FAAP, Elizabeth D. Barnett, MD, FAAP, Ruth Lynfield, MD, FAAP, Mark H. Sawyer, MD, FAAP Bax CE, Clark AK, Oboite M, Treat JR. A case of disseminated Lyme disease in a child with skin of color. Pediatr Dermatol. 2021 Nov;38 Suppl 2:140-141. doi: 10.1111/pde.14770. Epub 2021 Sep 13. PMID: 34515362. Lipsett SC, Nigrovic LE. Diagnosis of Lyme disease in the pediatric acute care setting. Curr Opin Pediatr. 2016 Jun;28(3):287-93. doi: 10.1097/MOP.0000000000000339. PMID: 27138805. Shapiro ED. Borrelia burgdorferi (Lyme disease). Pediatr Rev. 2014 Dec;35(12):500-9. doi: 10.1542/pir.35-12-500. PMID: 25452659; PMCID: PMC5029759. Meissner HC, Steere AC. Management of Pediatric Lyme Disease: Updates From 2020 Lyme Guidelines. Pediatrics. 2022 Mar 1;149(3):e2021054980. doi: 10.1542/peds.2021-054980. PMID: 35229121. Bolourchi M, Silver ES, Liberman L. Advanced Heart Block in Children with Lyme Disease. Pediatr Cardiol. 2019 Mar;40(3):513-517. doi: 10.1007/s00246-018-2003-8. Epub 2018 Oct 31. PMID: 30377753. Chason ME, Monaghan M, Wang J, Cheng Y, DeBiasi RL. Symptom Resolution in Pediatric Patients With Lyme Disease. J Pediatric Infect Dis Soc. 2019 May 11;8(2):170-173. doi: 10.1093/jpids/piy067. PMID: 30060012. 2021. "Prevention of Mosquitoborne and Tickborne Infection", Red Book: 2021–2024 Report of the Committee on Infectious Diseases, Committee on Infectious Diseases, American Academy of Pediatrics, David W. Kimberlin, MD, FAAP, Elizabeth D. Barnett, MD, FAAP, Ruth Lynfield, MD, FAAP, Mark H. Sawyer, MD, FAAP Centers for Disease Control and Prevention. Preventing Tick Bites on People [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; Sept 2019 [cited 2022 March 30]. Available from: https://www.cdc.gov/lyme/prev/on_people.html

In this episode, Dr. Sheliza Halani interviews special guest Dr. Alon Vaisman (Infectious Diseases) on the Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).They discuss the definitions of severity of C. difficile, recommendations for current treatment and testing, prophylaxis and surgical management options. Producer and Host: Dr. Sheliza HalaniGuest: Dr. Alon Vaisman (Infectious Diseases)Sound Editing: Dr. Alison LaiSupport the show

In this week's episode we dig into the microbiome with world renowned expert Dr. Ghannoum.  We chat about what the microbiome is, and that is not JUST bacteria.  How the microbiome not just in your gut, the health implications of these colonies, what disrupts them and what feeds them.   No one has done more research of the microbiome that Dr G., and he continues to research more everyday.Dr G is the Co-Founder and Chief Scientific Officer, BiohmHealthReceived an MSc in Medicinal Chemistry and his PhD in Microbial Physiology from the University of Technology in Loughborough, England, and an MBA from the Weatherhead School of Management at Case Western Reserve University, Cleveland, OH. A tenured Professor and Director of the Integrated Microbiome Core and Center for Medical Mycology, and Case Western Reserve University and University Hospitals Cleveland Medical Center. Published > 450 peer reviewed publication and 6 scientific books, and was on the top 1% of cited Scientists Worldwide Established a multidisciplinary Center of Excellence that combines basic and translational research that spans test tube to the bedside capabilities. He pioneered studies on the fungal communities residing in and on our body and coined the term ‘Mycobiome”. Awarded the Rhoda Benham Award from the MMSA, and the Freedom to Discover Award from Bristol-Myers Squibb for his outstanding and meritorious contributions to the fields of medical mycology and microbial biofilms. Fellow of the Infectious Disease Society of America (IDSA), past President of the Medical Mycological Society of the Americas (MMSA). Fellow of the American Academy of Microbiology (FAAM), and the European Society of Clinical  Microbiology and Infectious Diseases (FESCMID).An entrepreneur-scientist who has launched a number of companies focused on the treatment of biofilm infections, as well as microbial dysbiosis.

Recognized as 1 of the 50 most notable designers over the last 50 years, Brian Roderman is the President and Co-Owner of IN2 Innovation, an experience innovation design agency that provides a global range of services from inspiration to integration. IN2 Innovation currently has offices located in Dallas, Austin, and Atlanta.Brian has worked in the design consultancy business for over 30 years and is frequently a featured speaker on design and innovation at events and symposiums worldwide. He has extensive design experience in consumer electronics, consumer products, housewares, transportation, telecommunications, and business-to-business industries for clients such as TopGolf, Frigidaire, Interstate Batteries, Newell Brands, Marriott, and many others.He is active with the Industrial Design Society of America (IDSA), having held six terms on the IDSA National Board of Directors. He was recently awarded a Fellowship within the society along with the top notable designer's recognition honor.Brian's Power statements on Experience Design: UX design is more than just digital design.The experience revolution has begun, and we are in for a 30 year run.A True User Experience occurs when human senses are engaged (the more the better) and emotional responses are transmitted. A brand can intersect with the True User Experience through combined products and services in digital and physical means. We have long tried to adapt to technology, now we are asking technology to adapt to us.Experience design brings the human back into the center of the focus. We need designers who can create a balanced world of experiences.  We need holistic experience designers.Join our weekly discussions on Clubhouse:https://www.clubhouse.com/club/the-variableOther (non-recorded) Clubhouse events hosted by Justin Adleffhttps://www.clubhouse.com/club/objects-experiences?utm_source=clubhouse&utm_medium=share_club&utm_campaign=hAr6ifilAK2P84UTJTMbmw-27939LINKS:Support The Variablewww.patreon.com/thevariabledesignWEBSITE: www.thevariable.designUPCOMING EVENTS: https://www.thevariable.design/qnaNOMINATE STUDENTS FOR SPOTLIGHT: https://www.thevariable.design/spotlightBLOG: https://www.thevariable.design/podcast_____________________________________________DISCORD ►► https://discord.gg/vpypTgPEvYTWITTER ►► https://twitter.com/thevariable_IDFACEBOOK ►► https://www.facebook.com/thevariable.design/INSTAGRAM ►► https://www.instagram.com/thevariable.design/LINKEDIN ►► https://www.linkedin.com/company/the-variable-designSupport the show

This week on Pharm5: FTC launches investigation into PBMs COVID vaccines coming soon for kids